Predictive Oncology Inc
POAI5.950USD
0.000
收盤 12/24, 13:00（美東）報價延遲15分鐘
4.56M總市值
虧損本益比TTM
關於 Predictive Oncology Inc 公司
Predictive Oncology Inc. is engaged in using artificial intelligence (AI) and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The Company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy when a tumor sample responds to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Through AI, it uses its proprietary biobank of 150,000+ cancer tumor samples, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of drug development. The Company offers a suite of solutions for oncology drug development from early discovery to clinical trials.
Predictive Oncology Inc簡介
公司代碼POAI
公司名稱Predictive Oncology Inc
上市日期Dec 18, 2009
CEOVennare (Raymond F)
員工數量23
證券類型Ordinary Share
年結日Dec 18
公司地址91 43Rd Street
城市PITTSBURGH
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編15201
電話14124321500
網址https://predictive-oncology.com/
公司代碼POAI
上市日期Dec 18, 2009
CEOVennare (Raymond F)
Predictive Oncology Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Joshua Blacher
Mr. Joshua Blacher
Interim Chief Financial Officer
Interim Chief Financial Officer
6.47K
--
Mr. Raymond F. Vennare
Mr. Raymond F. Vennare
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
6.43K
-26.95%
Dr. Daniel E. (Dan) Handley, Ph.D.
Dr. Daniel E. (Dan) Handley, Ph.D.
Independent Director
Independent Director
5.45K
--
Dr. Veena Rao, Ph.D.
Dr. Veena Rao, Ph.D.
Independent Director
Independent Director
4.92K
--
Mr. Thomas McLaughlin
Mr. Thomas McLaughlin
Chief Investment Officer
Chief Investment Officer
--
--
Ms. Sara Turken
Ms. Sara Turken
General Counsel
General Counsel
--
--
Mr. Shawn P. Matthews
Mr. Shawn P. Matthews
Director
Director
--
--
Dr. Matthew J. Hawryluk, Ph.D.
Dr. Matthew J. Hawryluk, Ph.D.
Independent Director
Independent Director
--
--
Mr. Gregory S. St. Clair, Sr.
Mr. Gregory S. St. Clair, Sr.
Independent Director
Independent Director
--
--
Mr. Chuck (Charles) Nuzum, Sr.
Mr. Chuck (Charles) Nuzum, Sr.
Lead Independent Director
Lead Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Joshua Blacher
Mr. Joshua Blacher
Interim Chief Financial Officer
Interim Chief Financial Officer
6.47K
--
Mr. Raymond F. Vennare
Mr. Raymond F. Vennare
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
6.43K
-26.95%
Dr. Daniel E. (Dan) Handley, Ph.D.
Dr. Daniel E. (Dan) Handley, Ph.D.
Independent Director
Independent Director
5.45K
--
Dr. Veena Rao, Ph.D.
Dr. Veena Rao, Ph.D.
Independent Director
Independent Director
4.92K
--
Mr. Thomas McLaughlin
Mr. Thomas McLaughlin
Chief Investment Officer
Chief Investment Officer
--
--
Ms. Sara Turken
Ms. Sara Turken
General Counsel
General Counsel
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Luo (Weiyu)
2.89%
SLN Capital Ltd
1.73%
Diametric Capital
0.15%
Blacher (Joshua)
0.04%
Vennare (Raymond F)
0.04%
其他
95.15%
持股股東
持股股東
佔比
Luo (Weiyu)
2.89%
SLN Capital Ltd
1.73%
Diametric Capital
0.15%
Blacher (Joshua)
0.04%
Vennare (Raymond F)
0.04%
其他
95.15%
股東類型
持股股東
佔比
Individual Investor
3.19%
Corporation
1.73%
Investment Advisor/Hedge Fund
0.15%
其他
94.93%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
37
7.39K
0.21%
-26.00K
2025Q2
44
299.51K
2.93%
-288.64K
2025Q1
50
299.35K
3.35%
-293.31K
2024Q4
56
353.94K
4.97%
-213.96K
2024Q3
54
322.08K
5.97%
-246.26K
2024Q2
57
408.73K
8.00%
-114.07K
2024Q1
66
484.20K
11.91%
-86.59K
2023Q4
66
502.45K
12.36%
-67.11K
2023Q3
69
499.46K
12.41%
-50.95K
2023Q2
67
353.15K
8.84%
-144.84K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Blacher (Joshua)
6.47K
0.85%
+6.47K
--
Sep 09, 2025
Vennare (Raymond F)
8.81K
1.16%
+8.33K
+1753.89%
Sep 09, 2025
Nuzum (Charles Lee Sr)
6.31K
0.83%
+4.31K
+216.25%
Sep 09, 2025
St Clair (Gregory Sr)
5.72K
0.75%
+4.31K
+305.17%
Sep 09, 2025
Chung-Welch (Nancy)
5.60K
0.73%
+4.31K
+334.78%
Sep 09, 2025
Handley (Daniel E)
5.45K
0.71%
+4.31K
+379.91%
Sep 09, 2025
Hawryluk (Matthew)
4.95K
0.65%
+4.31K
+681.20%
Sep 09, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Sep 25, 2025
Merger
15→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
公告日期
類型
比率
Sep 25, 2025
Merger
15→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
常見問題
Predictive Oncology Inc的前五大股東是誰？
Predictive Oncology Inc的前五大股東如下：
Blacher (Joshua)持有股份：6.47K佔總股份比例：0.85%。
Vennare (Raymond F)持有股份：8.81K佔總股份比例：1.16%。
Nuzum (Charles Lee Sr)持有股份：6.31K佔總股份比例：0.83%。
St Clair (Gregory Sr)持有股份：5.72K佔總股份比例：0.75%。
Chung-Welch (Nancy)持有股份：5.60K佔總股份比例：0.73%。
Blacher (Joshua)持有股份：6.47K佔總股份比例：0.85%。
Vennare (Raymond F)持有股份：8.81K佔總股份比例：1.16%。
Nuzum (Charles Lee Sr)持有股份：6.31K佔總股份比例：0.83%。
St Clair (Gregory Sr)持有股份：5.72K佔總股份比例：0.75%。
Chung-Welch (Nancy)持有股份：5.60K佔總股份比例：0.73%。
Predictive Oncology Inc的前三大股東類型是什麼？
Predictive Oncology Inc 的前三大股東類型分別是：
Luo (Weiyu)
SLN Capital Ltd
Diametric Capital
Luo (Weiyu)
SLN Capital Ltd
Diametric Capital
有多少機構持有Predictive Oncology Inc(POAI)的股份？
截至2025Q3，共有37家機構持有Predictive Oncology Inc的股份，合計持有的股份價值約為7.39K，占公司總股份的0.21% 。與2025Q2相比，機構持股有所增加，增幅為-2.72%。
哪個業務部門對Predictive Oncology Inc的收入貢獻最大？
在--，--業務部門對Predictive Oncology Inc的收入貢獻最大，創收--，占總收入的--% 。
